CureVac

CureVac

File Photo

EU to okay deal with CureVac for supply of up to 405 million Covid vaccines

FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski

Germany grants BioNTech, CureVac $745 mln to speed up Covid-19 vaccine work

Representational Image. Photo: Reuters

Curevac gets 252 mln euro German grant for Covid-19 vaccine

Representational Image. Photo: Reuters

EU, CureVac in talks on 225 million doses of potential Covid-19 vaccine

Representational Image. Photo: Reuters

CureVac doesn't rule out accelerated approval for Covid-19 vaccine

Representational Image. Photo: Reuters

German Covid-19 vaccine developer looks to raise up to $213 mln in US IPO

Photo: Collected

GSK buys 10% of CureVac in vaccine tech deal

Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020/ Reuters

EU in talks with Moderna, BioNtech, CureVac to secure possible Covid vaccines - sources

FILE PHOTO: A vaccination against the coronavirus disease (Covid-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach

Tesla to make molecule printers for German Covid-19 vaccine developer CureVac

Representational Image. Photo: Reuters

Coronavirus vaccine could be on market in mid-2021 - CureVac

Representational Image. Photo: Reuters

Germany's CureVac to launch human trial of experimental coronavirus vaccine

FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (Covid-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. REUTERS/Andreas Gebert

Coronavirus vaccine maker CureVac plans US listing in July

Representational Image. Photo: Reuters

Germany to buy stake in CureVac as world races for Covid-19 vaccine